Clinical Practice Guidelines For Diagnosis Research Articles

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

A. M. Vannucchi1, T. Barbui2, F. Cervantes3, C. Harrison4, J.-J. Kiladjian5, N. Kroger6, J. Thiele7 & C. Buske8 on behalf of the ESMO Guidelines Committee* Department of Experimental and Clinical Medicine, University of Florence, Florence; Hematology and Foundation for Research, Ospedale Papa Giovanni XXIII, Bergamo, Italy; Department of Hematology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain; Department of Haematology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK; Centre d’Investigations Cliniques (INSERM CIC1427), Hopital Saint-Louis and Paris Diderot University, Paris, France; Department of Stem Cell Transplantation, University Hospital Hamburg, Hamburg; University of Cologne, Cologne; Comprehensive Cancer Center Ulm, Institute of Experimental Cancer Research, University Hospital Ulm, Ulm, Germany

Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up

Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

R. Dummer1, A. Hauschild2, N. Lindenblatt3, G. Pentheroudakis4 & U. Keilholz5, on behalf of the ESMO Guidelines Committee* Department of Dermatology, University Hospital Zurich, Zurich, Switzerland; Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany; Division of Plastic and Reconstructive Surgery, University Hospital Zurich, Zurich, Switzerland; Ioannina University Hospital, Ioannina, Greece; Charite Comprehensive Cancer Center, Charite-Universitatsmedizin, Berlin, Germany

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

H. Tilly1, M. Gomes da Silva2, U. Vitolo3, A. Jack4, M. Meignan5, A. Lopez-Guillermo6, J. Walewski7, M. Andre8, P. W. Johnson9, M. Pfreundschuh10 & M. Ladetto11, on behalf of the ESMO Guidelines Committee* Centre Henri-Becquerel, Universite de Rouen, Rouen, France; Portuguese Institute of Oncology, Lisbon, Portugal; A.O. Citta della Salute e della Scienza di Torino, Turin, Italy; St James’s University Hospital, Leeds, UK; Henri Mondor University Hospital, Creteil, France; Hospital Clinic, Barcelona, Spain; Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warsaw, Poland; CHU Dinant-Godinne, UCL Namur, Yvoir, Belgium; Cancer Research UK, University of Southampton, Southampton, UK; Innere Medizin I, Universitat des Saarlandes, Hamburg, Germany; Divisione di Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

F. d’Amore1, P. Gaulard2, L. Trumper3, P. Corradini4, W.-S. Kim5, L. Specht6, M. Bjerregaard Pedersen1 & M. Ladetto7, on behalf of the ESMO Guidelines Committee* Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; Department of Pathology, Hopital Henri Mondor, Creteil, France; Department of Hematology and Oncology, Georg August University, Gottingen, Germany; Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, Milan, Italy; Department of Medicine, Division of Hematology-Oncology, Samsung Medical Center, Seoul, Korea; Department of Oncology and Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; Divisione di Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

K. Fizazi1, F. A. Greco2, N. Pavlidis3, G. Daugaard4, K. Oien5 & G. Pentheroudakis3, on behalf of the ESMO Guidelines Committee* Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Tennessee Oncology, Centennial Medical Center, Nashville, USA; Department of Medical Oncology, University of Ioannina, Ioannina, Greece; Department of Oncology 5073, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; University of Glasgow, Institute of Cancer Sciences, Glasgow, UK

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

13‐ICML Satellite symposia programs (updated on May 9, 2015)

13‐ICML Satellite symposia programs (updated on May 9, 2015)

Clinical practice guidelines for the diagnosis and management of acute otitis media (AOM) in children in Japan - 2013 update.

To (1) indicate methods of diagnosis and testing for childhood (<15 years) acute otitis media (AOM) and (2) recommend methods of treatment in accordance with the evidence-based consensus reached by the Subcommittee of Clinical Practice Guideline for Diagnosis and Management of AOM in Children (Subcommittee of Clinical Practice Guideline), in light of the causative bacteria and their drug sensitivity of AOM in Japan. We investigated the most recently detected bacteria causing childhood AOM in Japan as well as antibacterial sensitivity and the worldwide distinct progress of vaccination, produced Clinical Questions concerning the diagnosis, testing methods, and treatment of AOM, searched literature published during 2000-2004, and issued the 2006 Guidelines. In the 2009 and 2013 Guidelines, we performed the same investigation with the addition of literature, which were not included in the 2006 Guidelines and published during 2005-2008 and during 2009-2012, respectively. We categorized AOM as mild, moderate, or severe on the basis of tympanic membrane findings and clinical symptoms, and presented recommended treatment for each degree of severity. Accurate assessment of tympanic membrane findings is important for judging the degree of severity and selecting a method of treatment. Some of new antimicrobial agents and pneumococcal vaccination are recommended as new treatment options.

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

D. A. Eichenauer1, A. Engert1, M. Andre2, M. Federico3, T. Illidge4, M. Hutchings5, & M. Ladetto6 on behalf of the ESMO Guidelines Working Group* First Department of Internal Medicine, University Hospital Cologne and German Hodgkin Study Group (GHSG), Cologne, Germany; CHU Dinant-Godinne, UCL Namur, Yvoir, Belgium; Department of Oncology, Hematology and Respiratory Diseases, University of Modena and Reggio Emilia, Modena, Italy; Institute of Cancer Sciences, University of Manchester, Manchester, UK; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Divisione di Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

E. Van Cutsem1, A. Cervantes2, B. Nordlinger3 & D. Arnold4, on behalf of the ESMO Guidelines Working Group* Digestive Oncology, University Hospitals Leuven, Leuven, Belgium; Department of Hematology and Medical Oncology, INCLIVA, University of Valencia, Valencia, Spain; Department of General Surgery and Surgical Oncology, Hopital Ambroise Pare, Assistance Publique – Hopitaux de Paris, Paris, France; Klinik fur Tumorbiologie, Freiburg, Germany

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Mantle cell lymphoma (MCL) is a less frequent subtype of lymphoid malignancies and represents 6%–9% of malignant lymphoma in Western Europe. The annual incidence of this disease has increased during recent decades to 1–2/100 000 recently. MCL is more common in males than in women with a 3 : 1 ratio.

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Primary lung cancer is the most common malignancy after non-melanocytic skin cancer with deaths from lung cancer exceeding those from any other type of malignancy worldwide [1]. While it has been the most important cause of cancer mortality in men since the 1960s, it has equalled breast cancer as a cause of mortality in women since the 1990s. To date, prevention and smoking cessation are still the main methods to reduce the death toll [2]. Lung cancer is still increasing both in incidence and mortality worldwide.

Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Squamous cell carcinoma of the anus (SCCA) is a rare cancer but its incidence is increasing throughout the world, and is particularly high in the human immunodeficiency virus positive (HIVþ) population. A multidisciplinary approach is mandatory (involving radiation therapists, medical oncologists, surgeons, radiologists and pathologists). SCCA usually spreads in a loco-regional manner within and outside the anal canal. Lymph node involvement at diagnosis is observed in 30%e40% of cases while systemic spread is uncommon with distant extrapelvic metastases recorded in 5%e8% at onset, and rates of metastatic progression after primary treatment between 10 and 20%. SCCA is strongly associated with human papilloma virus (HPV, types 16e18) infection. The primary aim of treatment is to achieve cure with loco-regional control and preservation of anal function, with the best possible quality of life. Treatment dramatically differs from adenocarcinomas of the lower rectum. Combinations of 5FU-based chemoradiation and other cytotoxic agents (mitomycin C) have been established as the standard of care, leading to complete tumour regression in 80%e90% of patients with locoregional failures in the region of 15%. There is an accepted role for surgical salvage. Assessment and treatment should be carried out in specialised centres treating a high number of patients as early as possible in the clinical diagnosis. To date, the limited evidence from only 6 randomised trials [1,2,3,4,5,6,7], the rarity of the cancer, and the different behaviour/natural history depending on the predominant site of origin, (the anal margin, anal canal or above the dentate line) provide scanty direction for any individual oncologist. Here we aim to provide guidelines which can assist medical, radiation and surgical oncologists in the practical management of this unusual cancer. 2014 Elsevier Ltd. All rights reserved.